Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 8
Submit an article Journal homepage
250
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma

Peter A. ForsbergDivision of Hematology, University of Colorado, Aurora, CO, USA; Correspondence[email protected]
,
Andrew HammesUniversity of Colorado, School of Public Health, Aurora, CO, USA;
,
Diana AbbottUniversity of Colorado, School of Public Health, Aurora, CO, USA;
,
Daniel W. SherbenouDivision of Hematology, University of Colorado, Aurora, CO, USA;
,
Adriana RossiDivision of Hematology and Oncology, Weill Cornell Medical College, New York, NY, USA;
,
David JayabalanDivision of Hematology and Oncology, Weill Cornell Medical College, New York, NY, USA;
,
Ruben NiesvizkyDivision of Hematology and Oncology, Weill Cornell Medical College, New York, NY, USA;
,
Tomer M. MarkDivision of Hematology, University of Colorado, Aurora, CO, USA;
&
Scott ElyTranslational Pathology/Translational Medicine, Bristol-Myers Squibb, Princeton, NJ, USA
 show all
Pages 2085-2087 | Received 30 Jul 2018, Accepted 18 Nov 2018, Published online: 11 Jan 2019

References

  • Laubach J, Garderet L, Mahindra A, et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2016;30:1005–1017.
  • Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443–2448.
  • Greipp PR, Lust JA, O'Fallon WM, et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382–3387.
  • Steensma DP, Gertz MA, Greipp PR, et al. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood. 2001;97:2522–2523.
  • Madan S, Kyle RA, Greipp PR. Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma. Mayo Clin Proc. 2010;85:300.
  • Ely S, Di Liberto M, Niesvizky R, et al. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res. 2005;65:11345–11353.
  • Nardiello T, Jungbluth AA, Mei A, et al. MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clin Cancer Res. 2011;17:4309–4319.
  • Jungbluth AA, Ely S, DiLiberto M, et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. *The first 2 authors contributed equally to this study and manuscript. Blood. 2005;106:167–174.
  • Ely S, Forsberg P, Ouansafi I, et al. Cellular proliferation by multiplex immunohistochemistry identifies high-risk multiple myeloma in newly diagnosed, treatment-naive patients. Clin Lymphoma Myeloma Leuk. 2017;17:825–833.
  • Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473.
  • Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23:2210–2221.
  • Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012;120:1060–1066.
  • Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120:1067–1076.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.